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The 5-lipoxygenase pathway (5-LOX) has been implicated in the development of cardiovas-
cular disease and studies have suggested that genetic polymorphisms related to key
enzymes in this pathway may confer risk of myocardial infarction (MI). This study investi-
gated the association of pre-selected genetic polymorphisms in four candidate genes of 5-
LOX (arachidonate 5-lipoxygenase and its activating protein (ALOX-5 and FLAP), leukotri-
ene A4 hydroxylase (LTA4-H) and leukotriene C4 synthase (LTC4-S)) with incident MI.
Methods
In a Danish cohort including 57,053 participants, aged 50–64 at enrolment and recruited
from 1993–97, we conducted a case-cohort study including cases with incident MI and a
randomly selected sub cohort of 3,000 participants. Cases were identified from national reg-
istries through July 2013. A total of 22 SNPs were selected and genotyped using the com-
mercially available KASP™ assay. A tandem-repeat polymorphism, located in the ALOX-5
gene, was genotyped by multi-titre plate sequencing. Haplotypes were inferred using
PHASE 2.1.
Results
During a median follow-up of 17.0 years we identified 3,089 cases of incident MI. In FLAP,
two SNPs were negatively associated with incident MI (rs9551963 & rs17222842) while one
SNP (rs2247570) located in LTA4-H, was associated with higher risk of MI when comparing
subjects with two copies of the variant allele to homozygotes for the wild type. However,
only rs17222842 remained significantly associated with MI after correcting for multiple test-
ing. Furthermore, the promoter polymorphism rs59439148 was associated with risk of MI in
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men. For male carriers of two variant alleles we found a hazard ratio of 1.63 (95% CI:
1.06;2.52) compared to homozygotes for the wild type. Previously described haplotypes
(Hap-A -B, -E and -K) were not associated with MI in our population.
Conclusion
In conclusion, some common polymorphisms in the 5-lipoxygenase pathway were modestly
associated with incident MI, suggesting a potential role for this pathway in the development
of cardiovascular disease.
Introduction
Atherosclerosis is a multifactorial disease involving both environmental and genetic factors. In
recent years, focus has turned on the complex cascade of inflammatory processes that takes
place in the vessel wall and within atherosclerotic plaques [1,2]. In this context the 5-lipoxy-
genase (5-LOX) pathway has received attention. Thus, the 5-LOX pathway metabolizes arachi-
donic acid (AA), leading to the formation of highly pro-inflammatory lipid mediators called
leukotrienes (LTs) [3]. The 5-LOX pathway consists of four key enzymes, where arachidonate
5-lipoxygenase (ALOX-5) and the ALOX-5 activating protein (FLAP) constitutes the first
enzymatic step followed by conversion to either leukotriene C4 synthase (LTC4-S) or leukotri-
ene B4 hydroxylase (LTB4-H) resulting in the formation of either cysteinyl leukotrienes or B-
series leukotrienes, respectively (Fig 1).
Evidence at multiple levels, including animal, biochemical and human studies, has linked
this pathway and the bioactive LTs to the development of atherosclerosis and athero-throm-
botic disease [3–7]. Thus, in a mouse model, it was demonstrated that the knock out of the
ALOX-5 gene led to a high resistance against the development of atherosclerosis [8]. Other
aspects of the 5-LOX pathway have been implicated in atherosclerosis traits in animal studies,
including the leukotriene B4 –receptor [9,10] and the FLAP gene [11]. Furthermore, studies
on human atherosclerotic plaques have identified the presence of 5-LOX enzymes and levels of
ALOX-5 were higher in the more advanced plaques [12]. In addition, high levels of ALOX-5
and LTA4-H in human plaques have been associated with symptoms of plaque instability
[13,14], suggesting a key role of the 5-LOX pathway in late stages of atherosclerosis and athero-
thrombotic events.
A number of epidemiological studies have examined four candidate genes, encoding the
enzymes involved in the 5-LOX pathway. Most attention has been focused on ALOX-5 and
FLAP, where Dwyer et al. examined a tandem repeat polymorphism in the promoter region of
ALOX-5 that was associated with higher intima-media thickness of the carotid arteries, a
marker of atherosclerosis, when comparing carriers of the variant allele with homozygotes of
the wild type allele [15]. This polymorphism has been investigated in a number of studies with
different endpoints, including ischemic stroke and MI [16–20], but the results have been
conflicting.
In a genome-wide association study, the deCODE investigators identified FLAP as an
important gene involved in atherothrombotic disease and reported two haplotypes (Hap-A
and Hap-B) that were associated with higher risk of MI and stroke [21,22]. Some studies have
supported these findings [23–27] while others did not find these haplotypes to be associated
with risk of MI or stroke [19,28–30].
Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Myocardial Infarction
PLOS ONE | DOI:10.1371/journal.pone.0167217 November 28, 2016 2 / 19
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
The deCODE investigators also defined a risk haplotype (Hap-K) for MI [31], covering the
LTA4-H gene which was confirmed by other investigators [19,32]. Following these studies,
Zhao et al. defined a new haplotype (Hap-E) that was associated with a lower risk of MI among
carriers compared to non-carriers [30].
Finally, two promoter polymorphisms have been identified in LTC4-S and investigated in
three studies, with conflicting results [33–35].
Thus, from previous studies on four candidate genes, encoding key enzymes in the 5-LOX
pathway, it has been suggested that genetic variants may be associated with atherosclerotic dis-
ease. Following a review of the literature, we selected 22 SNPs from these four candidate genes
to investigate the association with incident MI in a large Danish cohort study.
Materials and Methods
Study design and population
The Danish Diet, Cancer and Health study is a prospective cohort study, which has been
described in detail previously [36]. Briefly, 160,725 persons aged 50–64 years were invited
Fig 1. Schematic outline of the 5-LOX pathway leading to the formation of leukotrienes. The figure
gives a schematic overview of the formation of 4-series leukotrines from arachidonic acid. The first step is
catalysed by 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP), which is also the rate-limiting step
in the pathway. Next, leukotriene A4 is rapidly metabolised to either leukotriene B4 or the cysteinyl
leukotrienes by leukotriene A4-hydroxylase or leukotriene C4-synthase, respectively.
doi:10.1371/journal.pone.0167217.g001
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between December 1993 and May 1997. Eligible participants were born in Denmark, living in
the urban areas of Copenhagen and Aarhus and not registered with a cancer diagnosis in the
Danish Cancer Registry at the time of invitation. If a cancer diagnosis was found that was not
already recorded in the Cancer Registry at time of invitation, participants were excluded in
line with the intention-to-include criteria. Further, participants registered with a previous MI
or cardiac arrest were excluded as well. At baseline, each participant filled in a detailed ques-
tionnaire on diet, lifestyle, socio-economic status and medical history. Blood and adipose tis-
sue samples were collected.
For the present study we used a nested case-cohort design including all cases with incident
MI and a randomly selected sub cohort (n = 3,000) to represent the cohort. The study was con-
ducted in accordance with the Helsinki Declaration and all participants provided written
informed consent. The study, including the consent procedure, was approved by The Regional
Ethics Committee, North Denmark Region (approval number, N-20140071).
Selection and genotyping of SNPs
From a review of the current literature, we selected four candidate genes to examine the
5-LOX pathway (ALOX-5, FLAP, LTA4-H and LTC4-S). Next, 22 SNP markers were selected
based on previous reported associations with cardiovascular disease, with preference for coro-
nary artery disease, and a confirmed minor allele frequency (MAF) > 0.05 in Caucasians.
From whole blood, DNA was extracted using Kleargene™ XL DNA extraction kit (LGC
Genomics, Queens Road, Teddington, Middlesex, UK). Next, contaminants were removed by
washing and DNA was subsequently eluted into a low salt buffer. Extracted DNA were stored
at -20˚C.
SNP genotyping was performed by LGC Genomics using the commercially available
KASP™ genotyping assay. KASP is based on a competitive, allele specific PCR genotyping tech-
nique with a homogenous fluorescent based reporting system [37]. The reaction mix was ali-
quoted to standard 96-well plates containing DNA-samples from the study cohort, including
at least one "no template control" per plate. PCR was performed and the fluorescent signal was
analysed using a BMG PHERAstar plate reader (BMG Labtech Ltd., Aylesbury, UK). The anal-
ysis was performed according to the protocol provided by LGC Genomics [38]. SNP alleles
correspond to the positive/forward DNA-strand according to dbSNP, human assembly
GRCh38.p2 [39].
Genotyping of ALOX-5 tandem repeat polymorphism
The tandem repeat polymorphism was analysed by microtitre plate (MTP)-sequencing tech-
nique, using standard 96-well plates. PCR-products were prepared from genomic DNA, using
MyTaq™ DNA polymerase (Bioline US Inc.) along with the following primers: 5’-TCAGGA
GAGAACGAGTGAAC-3’ (forward) and 5’-GTCCAGGTGTCCGCATC-3’ (reverse). 40 reac-
tion cycles were performed at 55˚C. From the PCR-products, sequencing was done using an
ABI 3730XL DNA analyser (Thermo Fischer Scientific Inc.) and Chromatograms were inter-
preted by a trained laboratory technician, identifying the number of tandem-repeats for each
allele.
Outcome assessment
We identified all participants in the cohort who were registered with an incident diagnosis of
MI in the Danish National Patient Registry and/or the Danish Causes of Death Registry,
according to the International Classification of Disease (ICD) 8 (410.00–410.99) or ICD-10
(I21.0-I21.9) coding, during the study period. Furthermore, all cases of cardiac arrest (ICD-8:
Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Myocardial Infarction
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427.27 or ICD-10: I46.0-I46.9) were included if the arrest was considered to be of cardiac ori-
gin after validation in each individual case. An earlier study from our Department validated
the MI diagnosis from baseline through 2003 by complete review of all medical records and
found a positive predictive value above 92% when the diagnoses were obtained from a hospital
ward [40]. All validated cases of MI from this validation study were included as cases for the
present study. From January 2004 through July 2013 all participants with an incident MI diag-
nosed from a ward were readily accepted as cases without further validation. All other diagno-
ses of incident MI and cardiac arrest were validated by reviewing a complete list of diagnoses
and interventional procedures recorded in the Danish National Patient Registry for each
potential case.
Statistics
Allele frequencies were tested for Hardy—Weinberg equilibrium (HWE) in the sub cohort
using a chi-square test (X2-test). SNPs deviating from HWE (p< 0.05) were excluded from
further analysis. We inferred haplotypes for combinations of SNPs using the program PHASE,
version 2.1 [41,42]. In brief, the PHASE algorithm implements a Bayesian statistical method
for reconstructing haplotypes from observed genotype data, dealing with missing data by
imputing missing genotypes. The program constructs diplotypes for each individual with
probability estimates for each diplotype. Weights, from the probability estimates derived from
PHASE, were implemented in the analyses as described by French et al. [43].
SNPs were analyzed as categorical variables with two degrees of freedom, assuming a gen-
eral model of inheritance. To correct for multiple comparisons, we estimated the number of
independent tests within each candidate gene, taking into account the correlation between
SNPs by estimating the composite linkage disequilibrium (LD) correlation matrix from the
SNP data, as described by Gao et al. [44]. Next, p-values were adjusted according to the num-
ber of independent tests derived from the correlation matrix using Sidák corrections [45].
Haplotype analyses were performed for previously described haplotypes in a univariate model,
comparing the risk haplotype against all other haplotypes by including only the risk haplotype
in the Cox model. Additionally, we evaluated all common haplotypes within FLAP and
LTA4-H using a multivariate model. In this model, the most common haplotype was selected
as reference and all common haplotype combinations (frequencies > 1%) derived from
PHASE were compared to the common haplotype by including all haplotypes as covariates in
the Cox model, except for the most common haplotype. For both the uni- and multivariate
models, each haplotype was evaluated, comparing non-carriers with carriers of one or two
copies of the haplotype, assuming linearity for the haplotype effect [43,46].
Measures of association were assessed using Cox proportional hazards multivariate regres-
sion models with age as the time axis. In accordance with the case-cohort design, we used a
weighting scheme and robust variance estimates as described by Kalbfleisch and Lawless [47].
For the haplotype analyses, these weights were multiplied with the probability weights derived
from PHASE. Analyses were conducted for the whole study cohort and separately for men and
women, but the pooled analysis was considered as the primary. Participants were treated as at
risk from baseline until either MI, death, emigration or end of follow-up occurred.
To address potential confounding we adjusted for traditional risk factors for MI (model
A2) including smoking habits (never, former or current (<15 g/day, 15–25 g/day, >25 g/day)
smoker), body mass index (kg/m2), waist circumference (cm), physical activity (hours/week),
alcohol intake (g/day), educational level (basic school, higher education: 1–3 years or >3
years) and, for women, menopausal status (pre- or post-menopausal). All continuous variables
were included in the models as restricted cubic splines with five knots. Potential confounders
Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Myocardial Infarction
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were selected a priori based on current knowledge of risk factors for MI. In light of our pri-
mary exposure, being genetic polymorphisms, we did not expect confounding to be of major
concern.
The proportional hazards assumption was checked by visual inspection of log-log plots and
by evaluation of scaled Schoenfeld residuals with no violations of the assumption. P-values
(two-tailed) < 0.05 were considered statistically significant. STATA, version 14.1 (StataCorp,
College Station, TX, US) was used as statistical software.
Results
Population characteristics
From an initial 160,725 invited participants, a total of 57,053 (35%) accepted the invitation,
and were enrolled into the study. From these, we excluded 1,506 participants due to missing
baseline questionnaires or if recorded with a cancer diagnosis or having a previous MI or car-
diac arrest before baseline. In our study population we identified 3,089 cases of incident MI
during a median follow-up time of 17.0 years. After case verification, we excluded subjects for
whom information regarding one or more potential confounders was missing. Additionally,
255 subjects were missing DNA-samples. In total, 2,876 cases were included in the analyses
(Fig 2). For individual SNPs, genotype information was missing in 57 to 148 subjects.
As expected, traditional risk factors for MI were more prevalent among cases then in the
sub cohort (Table 1).
Association between ALOX-5 tandem-repeat polymorphism and MI
A tandem-repeat polymorphism, located close to the promoter region of ALOX-5, was ana-
lyzed by traditional sequencing (rs59439148). The genotype frequencies, according to the
number of hexamer-repeats (‘-CCCGCC-’) for the two alleles, are presented in Table 2. The
5-repeats allele was by far, the most common allele (84.4%). Next, the 4-repeats was the most
frequent variant allele observed (15.2%). Alleles with less than 4-repeats were rare (<1%). As a
result of the observed allele frequencies, we analyzed the tandem repeat defining the 5-repeats
allele as the wild type and alleles with less than 5-repeats as the variant alleles. Frequencies of
the constructed variant and wildtype are reported in Table 3. In men, the tandem-repeat poly-
morphism, rs59439148, was positively associated with MI when comparing homozygous carri-
ers of the variant with carriers of the wild type (HR = 1.63 with 95% CI: 1.06;2.52), suggesting
a recessive genetic effect (S1 Table). However, no association was seen for women and the
combined analyses were not statistically significant (Table 4), although the hazard ratios sug-
gested a positive association as in men.
In addition to the tandem-repeat polymorphism we also analyzed the SNP, rs12762303,
that was previously shown to be in close LD with the variant and wild type allele of the tan-
dem-repeat [29]. As anticipated, this SNP was in almost perfect LD with the tandem-repeat
polymorphism (D’ = 0.99), and the measures of association were very similar to the tandem-
repeat polymorphism.
Association of individual SNPs with MI
We genotyped 22 SNPs and examined associations with incident MI for each SNP individu-
ally. However, for two SNPs (rs17216473 and rs3776944), our assays were not able to detect
the variant allele after testing two different assays on the forward strand and afterwards two
assays on the reverse strand for each of the SNPs. The remaining 20 SNPs all displayed a
MAF > 0.05 (Table 3) and the allele frequencies were similar to observations in other
Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Myocardial Infarction
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populations of European origin, according to dbSNP [39]. No SNPs deviated from the Hardy
Weinberg equilibrium, when tested in the sub cohort.
In Table 4 we report hazard ratios for associations between individual SNPs and MI for the
study cohort. Results are presented for both heterozygous and homozygous carriers of the vari-
ant allele compared to homozygous carriers of the wild type, assuming a general model of
inheritance. Sex specific analysis are presented in the supplementary material (S1 Table).
For FLAP, the SNP rs9551963 was negatively associated with MI when comparing both het-
erozygous and homozygous carriers of the minor allele (A) with homozygous carriers of the
major allele (C), suggesting a dominant genetic effect. Results were similar across sex, but only
significant in men. For the combined analyses, we found a HR of 0.80 (95% CI: 0.68;0.95) for
homozygous carriers of the minor allele. Rs17222842 was also negatively associated with MI,
when comparing homozygous carriers of the minor allele with homozygotes of the major
(HR = 0.28 (95% CI:0.12;0.63)) in men, while no association was observed in women.
Ten SNPs were successfully genotyped in LTA4-H. Rs2247570 was positively associated
with MI in the combined analyses when comparing homozygous carriers of the minor (G) and
Fig 2. Flow chart of cohort selection process.
doi:10.1371/journal.pone.0167217.g002
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major allele (A), HR = 1.28 (95% CI: 1.03;1.59). This relationship was consistent in both men
and women, but associations were not statistically significant in the sex-stratified analyses. For
rs61937881, rs1978331 and rs17677715 we found a positive association between carriers of the
minor allele and MI compared with carriers of the major allele in women. However, the associ-
ations were not consistent among men, and the associations were not significant in the com-
bined analysis for men and women.
Finally, the SNP rs730012, located in proximity to the promoter region of LTC4-S was not
associated with MI in our data.
Association of haplotypes with MI
Results from haplotype analyses are presented in Tables 5 and 6. First, we tested single haplo-
types, previously identified in other studies, using all remaining haplotypes as reference
(Table 5). In the univariate analysis we did not find any of the previously described haplotypes
to be associated with MI. Next, we performed multivariate analyses including all common hap-
lotypes (haplotype frequency > 0.01) in the Cox-model, except for the most common haplo-
type, that served as reference (Table 6). When comparing carriers of each variant haplotype
with carriers of the most common haplotype in FLAP, one haplotype was negatively associated
with MI (GAGAAA). However, the association was modest. For LTA4-H the haplotype,
CGTTTATAAT, was negatively associated with incident MI.
Table 1. Baseline characteristics of the sub cohort and cases.
Men Women
Variable Sub cohort (n = 1,528) Cases (n = 2,048) Sub cohort (n = 1,330) Cases (n = 828)
Age (years) 56.3 (51.2;63.3) 57.7 (51.7;63.9) 56.4 (51.1;63.0) 59.3 (52.4;64.2)
Physical activity (hours/week) 2.5 (0.0;8.5) 2.0 (0.0;8.0) 2.5 (0.0;8.0) 2.0 (0.0;7.0)
BMI (kg/m2) 26.4 (22.7;31.2) 26.9 (23.2;32.2) 24.6 (20.9;31.1) 25.9 (20.9;33.2)
Waist circumference (cm) 95.0 (85.0;109.0) 97.0 (86.0;112.0) 80.0 (69.0;97.0) 84.0 (70.0;102.0)
Alcohol intake (g/day) 19.4 (3.3;61.9) 18.2 (2.5;62.7) 9.3 (1.2;34.8) 6.5 (0.5;32.1)
Smoking (% (n))
- Never smoker 25.7 (392) 18.1 (370) 42.8 (569) 27.1 (224)
- Former smoker 35.3 (540) 29.0 (594) 22.6 (301) 19.0 (157)
- <15 g/day 11.1 (169) 12.7 (259) 16.2 (215) 22.7 (188)
- 15–25 g/day 16.8 (256) 24.2 (495) 15.6 (207) 26.1 (216)
- >25 g/day 11.2 (171) 16.1 (330) 2.9 (38) 5.2 (43)
Educational level (% (n))
- Basic school 34.0 (520) 43.3 (887) 31.7 (422) 44.6 (369)
- Higher education, 1–3 years 42.2 (645) 37.0 (758) 49.9 (664) 45.8 (379)
- Higher education, >3 years 23.8 (363) 19.7 (403) 18.4 (244) 9.7 (80)
Menopausal status (% (n))
- Post-menopausal N/A N/A N/A N/A 59.6 (792) 69.9 (579)
- Pre-menopausal N/A N/A N/A N/A 31.1 (413) 17.0 (141)
Medical history (% (n))
- Hypertension 14.9 (227) 22.2 (454) 17.1 (227) 31.3 (259)
- Hypercholesterolaemia 8.4 (129) 12.0 (245) 6.5 (86) 13.0 (108)
- Diabetes mellitus 3.1 (48) 5.4 (111) 1.4 (19) 4.5 (37)
Abbreviations: BMI, Body mass index.
Continuous variables are reported as medians (10th;90th percentile) and categorical variables as percent (n).
doi:10.1371/journal.pone.0167217.t001
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LD maps produced from the Haploview software showed that most, but not all the selected
SNPs within FLAP and LTA4-H, were in high LD with one another. This raises the possibility
that some degree of recombination within the haplotype blocks had occurred in our popula-
tion (S1 Fig).
Discussion
In the large Danish Diet, Cancer and Health cohort we undertook a case-cohort study, investi-
gating the association between 20 pre-selected SNPs and incident MI. Single SNP analyses
identified two markers in FLAP that were negatively associated with MI (rs9551963 and
rs17222842), and for LTA4-H, rs2247570 was positively associated with MI. However, only
rs17222842 remained significantly associated with MI after adjusting for multiple testing. The
tandem repeat polymorphism in ALOX-5, rs59439148, was positively associated with MI for
men, while no association could be demonstrated in women. Furthermore, rs12762303 was in
almost perfect LD with rs59439148. Finally, we performed haplotype analyses testing the asso-
ciation between previously reported haplotypes and MI. No significant associations were
found.
In general, the associations of both single SNPs and haplotypes with MI were modest, and
for some markers the results differed between men and women. A frequent concern in genetic
association studies is the problem of multiple comparisons which raises the possibility of false
positive discoveries (type I errors). We addressed this issue by limiting the number of SNP
markers. Secondly, the number of statistical tests were minimized, e.g. for the single SNP anal-
ysis we tested the association with MI, assuming a general model of inheritance and refrained
from testing several specific models (e.g. dominant and recessive models). Some genetic asso-
ciation studies also adjust the significance threshold for multiple comparisons. A frequently
used method is the Bonferroni correction which adjusts the significance level by the number
of individual tests for each hypothesis. However, some authors have criticized this method for
being too conservative, and thereby introducing false negative discoveries (type II errors) [48].
Table 2. Distribution of genotypes for the ALOX-5 promoter polymorphism, according to number of tandem repeats (5’-GGGCGG-3’).
Genotype Sub cohort Cases
22 - - - -
23 - - - -
24 2 (0.07) 2 (0.07)
25 17 (0.59) 11 (0.38)
26 - - - -
33 - - - -
34 3 (0.10) 1 (0.03)
35 1 (0.03) 3 (0.10)
36 - - - -
44 73 (2.55) 82 (2.85)
45 717 (25.09) 679 (23.61)
46 - - - -
55 2,004 (70.12) 2,039 (70.90)
56 - - - -
66 - - 1 (0.03)
Abbreviations: ALOX-5, Arachidonate 5-lipoxygenase.
Reported as number of subjects with frequencies in parentheses (%). No observations are indicated with a dash.
doi:10.1371/journal.pone.0167217.t002
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This is particularly of concern when testing multiple SNP-markers that are tightly correlated,
and therefore not independent [44]. Accordingly, we used the method described by Gao et al.
[44] to correct for multiple comparisons, taking into account the possible correlation between
SNP-markers. We chose to report both the adjusted and the unadjusted p-values in Table 4.
While, in our opinion, the unadjusted p-values represents the most clear interpretation of the
data, they might be over optimistic and the results should be interpreted cautiously along with
the following limitations and strengths to the study design.
Strengths and limitations
This study was based on a large prospective cohort study, and holds the advantages of the pro-
spective design. There was a limited loss to follow-up and the assessment of outcome data was
thorough and complete. The ethnicity of the study population was homogenous and all partici-
pants were of Caucasian ancestry. Furthermore, information on several dietary factors, lifestyle
and other risk factors for MI was collected from the participants at baseline, allowing us to
adjust for potential confounding. A priori, we did not expect confounding to be a major issue
Table 3. Minor allele frequency for each SNP, selected from four candidate genes in the 5-LOX pathway.
SNP Genomic position Allele Sub cohort Cases
ALOX-5
rs12762303 10: 45373723 C/T 14.9 (833) 14.4 (809)
rs59439148 10: 4537413(2–7) V/W 15.8 (891) 15.3 (863)
FLAP
rs17222814 13: 30725416 A/G 11.0 (619) 10.6 (599)
rs4073259 13: 30732134 G/A 35.9 (2,004) 35.3 (1,983)
rs10507391 13: 30737959 A/T 32.9 (1,855) 32.4 (1,836)
rs4769874 13: 30752304 A/G 3.8 (213) 3.6 (200)
rs9551963 13: 30758410 A/C 50.3 (2,831) 48.2 (2,723)
rs9315050 13: 30761908 G/A 6.1 (342) 6.5 (366)
rs17222842 13: 30765980 A/G 10.7 (598) 9.7 (547)
LTC4-S
rs730012 5: 179793637 C/A 30.4 (1,705) 31.3 (1,765)
LTA4-H
rs61937881 12: 95999809 T/C 24.3 (1,349) 25.7 (1,440)
rs2660880 12: 96007474 A/G 6.8 (385) 6.8 (387)
rs6538697 12: 96009832 C/T 7.2 (408) 7.4 (419)
rs1978331 12: 96015423 C/T 38.3 (2,144) 39.9 (2,249)
rs17677715 12: 96020673 C/T 17.7 (998) 19.0 (1,076)
rs2247570 12: 96028599 G/A 29.5 (1,653) 30.8 (1,735)
rs2660898 12: 96032219 G/T 31.8 (1,783) 33.1 (1,872)
rs2540482 12: 96041102 G/A 22.5 (1,263) 22.1 (1,251)
rs2540477 12: 96043776 C/T 22.0 (1,238) 21.7 (1,228)
rs2660845 12: 96044775 G/A 26.0 (1,460) 25.6 (1,447)
rs2540475 12: 96047515 T/C 20.5 (1,159) 20.0 (1,131)
Abbreviations: SNP, Single nucleotide polymorphism; ALOX-5, Arachidonate 5-lipoxygenase; FLAP, 5-lipoxygenase activating protein; LTC4-S,
Leukotriene C4 synthase; LTA4-H, Leukotriene A4 hydroxylase.
Results presented as allele frequencies (n) for the minor allele(underlined). The two SNPs (rs17216473 & rs3776944) did not display variation in our study
population. Alleles correspond to the positive DNA-strand and genomic position are obtained from dbSNP, human assembly GRCh38.p2.
doi:10.1371/journal.pone.0167217.t003
Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Myocardial Infarction
PLOS ONE | DOI:10.1371/journal.pone.0167217 November 28, 2016 10 / 19
Table 4. Association of selected single nucleotide polymorphisms with incident myocardial infarction.
SNP Genotype Model A1* pa pb Model A2** pa pb
ALOX-5
rs12762303 T/T 1 (ref) 1 (ref)
C/T 0.94 (0.83;1.07) 0.34 - 0.96 (0.84;1.10) 0.55 -
C/C 1.27 (0.87;1.86) 0.22 - 1.37 (0.91;2.05) 0.13 -
rs59439148 W/W 1 (ref) 1 (ref)
W/V 0.94 (0.83;1.06) 0.31 - 0.96 (0.84;1.10) 0.52 -
V/V 1.23 (0.89;1.71) 0.21 - 1.35 (0.96;1.90) 0.09 -
FLAP
rs17222814 G/G 1 (ref) 1 (ref)
G/A 0.91 (0.79;1.05) 0.20 0.74 0.93 (0.80;1.08) 0.34 0.92
A/A 1.22 (0.72;2.05) 0.47 0.98 1.18 (0.66;2.10) 0.58 0.99
rs4073259 A/A 1 (ref) 1 (ref)
A/G 0.95 (0.84;1.07) 0.38 0.94 0.93 (0.82;1.06) 0.28 0.86
G/G 0.96 (0.81;1.15) 0.69 >0.99 0.96 (0.80;1.17) 0.70 >0.99
rs10507391 T/T 1 (ref) 1 (ref)
T/A 1.00 (0.89;1.12) 0.99 >0.99 0.99 (0.87;1.12) 0.83 >0.99
A/A 0.94 (0.78;1.14) 0.55 0.99 0.98 (0.80;1.19) 0.82 >0.99
rs4769874 G/G 1 (ref) 1 (ref)
G/A 0.96 (0.77;1.19) 0.72 >0.99 1.04 (0.83;1.31) 0.74 >0.99
A/A 0.27 (0.06;1.28) 0.10 0.47 0.33 (0.07;1.61) 0.17 0.67
rs9551963 C/C 1 (ref) 1 (ref)
C/A 0.86 (0.75;0.98) 0.03 0.14 0.83 (0.72;0.96) 0.01 0.07
A/A 0.85 (0.73;0.99) 0.04 0.21 0.80 (0.68;0.95) 0.01 0.05
rs9315050 A/A 1 (ref) 1 (ref)
A/G 1.03 (0.87;1.23) 0.71 >0.99 1.07 (0.89;1.28) 0.50 0.98
G/G 0.66 (0.28;1.55) 0.34 0.92 0.81 (0.34;1.93) 0.63 >0.99
rs17222842 G/G 1 (ref) 1 (ref)
G/A 0.97 (0.85;1.12) 0.73 >0.99 0.94 (0.81;1.10) 0.45 0.97
A/A 0.40 (0.22;0.73) 0.01 0.02 0.44 (0.24;0.82) 0.01 0.05
LTC4-S
rs730012 A/A 1 (ref) 1 (ref)
A/C 1.11 (0.99;1.25) 0.07 - 1.08 (0.95;1.22) 0.24 -
C/C 1.02 (0.83;1.24) 0.88 - 1.00 (0.81;1.24) 0.99 -
LTA4-H
rs61937881 C/C 1 (ref) 1 (ref)
C/T 1.05 (0.94;1.18) 0.40 0.95 1.02 (0.90;1.16) 0.71 >0.99
T/T 1.19 (0.94;1.50) 0.14 0.60 1.23 (0.96;1.58) 0.10 0.48
rs2660880 G/G 1 (ref) 1 (ref)
G/A 1.07 (0.91;1.27) 0.41 0.96 1.06 (0.89;1.28) 0.51 0.99
A/A 0.83 (0.41;1.70) 0.61 >0.99 0.80 (0.38;1.66) 0.54 0.99
rs6538697 T/T 1 (ref) 1 (ref)
T/C 1.01 (0.86;1.19) 0.88 >0.99 1.04 (0.87;1.23) 0.69 >0.99
C/C 0.99 (0.45;2.21) 0.99 >0.99 1.08 (0.48;2.43) 0.85 >0.99
rs1978331 T/T 1 (ref) 1 (ref)
T/C 1.06 (0.94;1.19) 0.38 0.94 1.06 (0.93;1.21) 0.38 0.94
C/C 1.15 (0.97;1.36) 0.10 0.48 1.19 (0.99;1.43) 0.06 0.30
(Continued )
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in this study, since the inherited genotype is subject to the principles of Mendelian randomiza-
tion. However, some evidence suggests that epigenetics, including environmental factors, may
influence on the expression of genes. We present the results for the crude model and an
adjusted model (A2) including the most important risk factors for MI to address potential con-
founding. Furthermore, gender was not expected to biologically modify the associations
between genotype and MI substantially, thus we considered the pooled analyses including
both men and women to be the primary analyses. Secondary analyses, for men and women
separately, were included as supplementary tables.
This study also had limitations. The selection of SNPs to cover the variation in each candi-
date gene was mostly based on findings by other studies and the results from genome wide
scans, using a large number of genetic markers. While this method has proven to be highly
effective in limiting the number of SNPs required for genotyping and the number of statistical
tests to be performed, this method did not cover all common genetic variation within the can-
didate genes. Therefore, we cannot completely rule out that our study failed to capture all
Table 4. (Continued)
SNP Genotype Model A1* pa pb Model A2** pa pb
rs17677715 T/T 1 (ref) 1 (ref)
T/C 1.05 (0.93;1.18) 0.43 0.97 1.04 (0.91;1.18) 0.56 0.99
C/C 1.25 (0.91;1.72) 0.17 0.66 1.29 (0.92;1.81) 0.14 0.59
rs2247570 A/A 1 (ref) 1 (ref)
A/G 1.00 (0.90;1.13) 0.94 >0.99 1.00 (0.88;1.13) 0.97 >0.99
G/G 1.23 (1.01;1.51) 0.04 0.22 1.28 (1.03;1.59) 0.03 0.15
rs2660898 T/T 1 (ref) 1 (ref)
T/G 1.09 (0.97;1.22) 0.17 0.66 1.07 (0.94;1.21) 0.32 0.90
G/G 1.09 (0.90;1.32) 0.37 0.94 1.12 (0.92;1.38) 0.26 0.84
rs2540482 A/A 1 (ref) 1 (ref)
A/G 0.95 (0.85;1.07) 0.38 0.94 0.95 (0.84;1.08) 0.44 0.97
G/G 1.05 (0.81;1.36) 0.74 >0.99 0.98 (0.74;1.30) 0.89 >0.99
rs2540477 T/T 1 (ref) 1 (ref)
T/C 0.95 (0.85;1.07) 0.39 0.95 0.95 (0.84;1.08) 0.45 0.97
C/C 1.08 (0.83;1.41) 0.58 0.99 1.03 (0.77;1.37) 0.85 >0.99
rs2660845 A/A 1 (ref) 1 (ref)
A/G 0.93 (0.83;1.05) 0.25 0.82 0.92 (0.82;1.04) 0.20 0.74
G/G 1.04 (0.83;1.31) 0.74 >0.99 1.04 (0.81;1.33) 0.76 >0.99
rs2540475 C/C 1 (ref) 1 (ref)
C/T 1.00 (0.89;1.12) 0.97 >0.99 0.98 (0.86;1.11) 0.72 >0.99
T/T 0.88 (0.67;1.17) 0.39 0.95 0.90 (0.67;1.21) 0.49 0.98
Abbreviations: SNP, Single nucleotide polymorphism; ALOX-5, Arachidonate 5-lipoxygenase; ALOX-5 AP, Arachidonate 5-lipoxygenase activating protein;
LTC4-S, Leukotriene C4 synthase; LTA4-H, Leukotriene A4 hydroxylase; LD, linkage disequilibrium.
The table displays hazard ratios from a weighted cox proportional hazards model. Alleles correspond to the positive DNA-strand according to dbSNP,
human assembly GRCh38.p2.
*Crude analyses. The pooled estimates are adjusted for sex.
**Adjusted analyses including sex(pooled analyses), smoking status, educational level, physical activity, BMI, waist circumference and alcohol
consumption.
aCrude p-value.
bAdjusted p-value corrected for multiple testing within each candidate gene. From the composite LD correlation matrix the number of independent tests (N)
were estimated. Using Sidák corrections, we then calculated the adjusted p-value as: pb = 1-(1-pa)N.
doi:10.1371/journal.pone.0167217.t004
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genetic variants that may be associated with our outcome. Two SNPs that were pre-selected
could not be successfully genotyped, and despite our efforts, four different assays were not able
to detect the minor allele for these two SNPs (rs17216473 and rs3776944).
Even though age was evenly distributed among men and women there were few female
cases, which made the confidence intervals wider for measures of association when analysing
data in women, and in particular for rare polymorphisms. The median follow-up was 17.0
years, and dietary measures were not assessed during the study period. A long follow-up
period allowed us to accumulate more outcome events, but subjects might change their life-
style and habits over time. Furthermore, changes in standard medical care and public aware-
ness of disease prevention might influence the participants’ risk profile and limit our ability to
address confounding. It is however unlikely that these changes affect measures of association
for genotypes and confounding was a minor concern in this study.
General discussion
Since the initial findings by Dwyer et al. [15] concerning ALOX-5, and later the deCODE
group identifying FLAP [21] and LTA4-H [31] as important genes in the 5-LOX pathway, a
number of studies have been undertaken in effort to replicate and add evidence to these stud-
ies. The ALOX-5 tandem repeat polymorphism (rs59439148) was first found to be associated
with higher intima-media thickness by Dwyer et al. but replications on cases with MI and cor-
onary artery disease verified by angiography, more clinically relevant endpoints, have yielded
conflicting results. Notably, two independent case-control studies on MI patients with North-
ern European origin (Caucasians) did not support an association between variant alleles and
MI for this polymorphism [17,18]. Another study in a mixed population of Caucasians and
African-Americans demonstrated a positive association, only in African-Americans [19]. Gen-
erally, studies were small and no studies reported data on men and women separately. In the
present study, we found a positive association between carriers of two variant alleles and MI,
but interestingly, the association was only present among men while there was no association
among women. The pooled analysis showed the same association as for men, but the test was
Table 5. Association of selected haplotypes in FLAP and LTA4-H with incident myocardial infarction.
Haplotype Freq. (%) Model A1* pa Model A2** pa
FLAP
Hap-A (GGAT) 14.0 0.97 (0.87;1.08) 0.58 0.92 (0.82;1.04) 0.18
Hap-B (AAG) 19.8 1.02 (0.93;1.12) 0.71 1.02 (0.92;1.13) 0.71
LTA4-H
Hap-K (CGTTTATGGC) 14.5 0.94 (0.85;1.05) 0.28 0.91 (0.82;1.02) 0.12
Hap-E (CCTGAA) 7.6 1.05 (0.91;1.21) 0.49 1.08 (0.93;1.26) 0.33
Abbreviations: FLAP, 5-lipoxygenase activating protein; LTA4-H, Leukotriene A4 hydroxylase.
The table displays hazard ratios from a weighted cox proportional hazards model. Haplotypes were defined as follows: Hap-A (rs17222814(G), rs4769874
(G), rs9551963(A), rs10507391(T)), Hap-B (rs10507391(A), rs9315050(A), rs17222842(G)), Hap-K (rs61937881(C), rs2660880(G), rs6538697(T),
rs1978331(T), rs17677715(T), rs2247570(A), rs2660898(T), rs2540482(G), rs2660845(G), rs2540475(C)), Hap-E (rs61937881(C), rs1978331(C),
rs17677715(T), rs2660898(G), rs2540482(A), rs2660845(A)). Alleles correspond to the positive DNA-strand according to dbSNP, human assembly
GRCh38.p2.
*Crude analyses. The pooled estimates are adjusted for sex.
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not statistically significant. While we have no apparent biological explanation for the differ-
ences between men and women, these inconsistencies may either be explained by random var-
iations in the small case-group (women) or by modification of the associations by gender. To
our knowledge, no previous study has presented data for men and women separately and we
have no data to compare to our own findings. Other SNPs have been explored in ALOX-5
[19,29] but only rs59439148 and SNPs linked to this polymorphism has been associated with
atherosclerosis traits. We confirmed the findings by Assimes et al. [29], that rs12762303 was in
near perfect LD with rs59439148 and measures of association were similar for these two
polymorphisms.
Looking at FLAP, Helgadottir et al. [21] identified two haplotypes, Hap-A and Hap-B, that
was associated with risk of MI in carriers of Hap-A compared to non-carriers in an Icelandic
population, while the same was true for Hap-B in a British population. The results were later
replicated in a Scottish cohort confirming a positive association for Hap-A, but not Hap-B,
with ischemic stroke [22]. In the present study, we could not confirm the association with MI
Table 6. Multivariate test of haplotypes in FLAP and LTA4-H and association with incident myocardial infarction.
Haplotype Freq. (%) Model A1* pa Model A2** pa
FLAP
GTGCAG 40.6 1 (ref) 1 (ref)
GAGAAG 16.1 0.95 (0.85;1.06) 0.35 0.94 (0.83;1.06) 0.29
GAGAAA 8.4 0.89 (0.77;1.02) 0.09 0.86 (0.74;0.99) 0.04
GAGCAG 3.7 1.19 (0.99;1.44) 0.07 1.18 (0.96;1.44) 0.12
GAACGG 3.5 0.88 (0.72;1.08) 0.23 0.96 (0.77;1.19) 0.71
GTGAAG 12.4 0.96 (0.85;1.08) 0.50 0.90 (0.79;1.02) 0.11
GTGAAA 1.7 0.82 (0.62;1.08) 0.17 0.85 (0.64;1.13) 0.26
GTGCGG 1.7 0.97 (0.73;1.29) 0.83 0.92 (0.67;1.26) 0.59
ATGAAG 10.6 0.92 (0.80;1.05) 0.21 0.92 (0.80;1.06) 0.27
LTA4-H
CGTTTATAAC 43.7 1 (ref) 1 (ref)
CGTTTATGGC 14.5 0.96 (0.86;1.07) 0.46 0.93 (0.82;1.05) 0.25
CGTTTATAAT 2.0 0.74 (0.57;0.96) 0.03 0.75 (0.56;0.99) 0.04
CGTCTGTAGC 3.1 1.03 (0.82;1.29) 0.81 1.03 (0.81;1.32) 0.80
CGTCTGTAAC 1.7 0.94 (0.70;1.26) 0.68 1.03 (0.76;1.40) 0.84
CGCCTAGAAC 5.5 1.04 (0.88;1.24) 0.63 1.04 (0.87;1.25) 0.65
CGCCTAGAAT 1.4 0.96 (0.70;1.31) 0.80 1.01 (0.73;1.39) 0.97
TGTCCGGGGC 6.2 1.12 (0.95;1.32) 0.19 1.16 (0.97;1.38) 0.10
TGTCCGGAAC 1.7 1.12 (0.86;1.47) 0.40 1.10 (0.83;1.45) 0.51
TGTCCGGAAT 9.7 1.05 (0.92;1.20) 0.49 1.03 (0.89;1.19) 0.69
TATCTGGAAT 5.5 1.00 (0.84;1.18) >0.99 1.00 (0.83;1.20) 0.99
Abbreviations: FLAP, 5-lipoxygenase activating protein; LTA4-H, Leukotriene A4 hydroxylase.
The table displays hazard ratios from a weighted cox proportional hazards model. All haplotypes with a frequency > 0.01 were included in the model except
for the most common haplotype that represented the reference. Haplotypes were constructed from the following SNPs in order: rs17222814, rs10507391,
rs4769874, rs9551963, rs9315050, rs17222842 (FLAP) and rs61937881, rs2660880, rs6538697, rs1978331, rs17677715, rs2247570, rs2660898,
rs2540482, rs2660845, rs2540475 (LTA4-H). Alleles correspond to the positive DNA-strand according to dbSNP, human assembly GRCh38.p2.
*Crude analyses. The pooled estimates are adjusted for sex.
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for Hap-A or -B. However, we found two individual SNPs within Hap-A and -B to be associ-
ated with MI when comparing homozygous carriers of the minor allele vs. the major allele
(rs9551963 and rs17222842). Other studies have found an association between individual
SNPs and MI in these haplotype blocks, but no consensus in favor of a certain SNP has been
agreed upon.
Finally, we analyzed ten SNPs covering a haplotype block in LTA4-H. Again, as for FLAP
we found some of the individual SNPs to be associated with incident MI but when analyzing
the previously reported haplotype (Hap-K) we did not find any association with MI in our
population.
Additionally, we performed a global haplotype analyses for FLAP and LTA4-H SNPs, in
order to explore new and unique haplotype combinations in our cohort. In these analyses we
included all common haplotypes inferred to our cohort in a multivariate model using the most
common haplotype as the reference haplotype. By this method we found sporadic associations
between haplotypes and MI but the associations were modest. This method of analyzing haplo-
types in a multivariate model is well established, but never the less, it has not been explored in
previous studies on 5-LOX genes.
In the following decade since the deCODE studies, a number of large genome wide associa-
tion studies (GWAS) exploring the role of common SNPs in MI has been conducted [49,50].
Notably, none of these studies have highlighted SNPs in the 5-LOX genes investigated in this
study as important risk variants in MI. However, while these large scale studies have the advan-
tage of covering the whole genome, they are not ideal in more specific hypothesis testing
involving specific pathway genes. In particular, the huge number of SNPs included in GWAS
implies rigorous adjustments of the significance level, increasing the risk of false negative dis-
coveries. We searched the publicly available database from three large GWAS, provided by the
CARDIoGRAMplusC4D Consortium [51], to compare our SNPs to the findings from these
large studies. None of the SNPs that were associated with MI in our study were analyzed in the
GWAS, and no direct comparison was possible.
In this context, the 5-LOX pathway have been linked to atherosclerosis and MI in a vari-
ety of studies. The key mechanism linking the 5-LOX pathway to atherosclerosis lies in the
formation of LT’s and their bioactive properties. Notably, the expression of multiple 5-LOX
enzymes has been linked to human atherosclerotic plaques and plaque development [12,13].
Furthermore, LT’s are known to exert several pro-inflammatory effects including increased
vascular permeability and chemo-attraction of monocytes [3,4]. Genetic association studies,
mainly candidate gene studies, have also provided some evidence of a link between the
5-LOX pathway and atherosclerotic disease, which is supported by the present study. How-
ever, despite a number of studies performed it has not been possible to identify and confirm
a functional polymorphism in most of the candidate genes, except for the tandem repeat
polymorphism in ALOX-5 (rs59439148), and the studies performed have been heteroge-
neous regarding design and results. These inconsistencies have led some authors to propose
a “pathway approach”, taking into account that each step of the 5-LOX pathway may have a
small influence on the outcome that can be detected when all steps are considered together.
Crosslin et al. [32] examined how the expression of 5-LOX genes depended on the genotype
of rs10507391, while another study found significant gene-gene interaction between a
selected SNP from each of three 5-LOX genes [35]. Other studies have investigated the pos-
sibility that substrates of the 5-LOX pathway might interact with genetic variants in a com-
plex environment where the effect of the genetic variant is dependent on substrate
availability [16,52].
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Conclusion
In this study we found single SNPs in three out of four candidate genes to be associated with
incident MI, collectively suggesting that the 5-LOX pathway may play a role in MI. However,
the associations were modest and only one SNP (rs17222842) remained significantly associ-
ated with MI after correcting for multiple testing. Association between MI and previously
reported haplotypes, Hap-A, -B, -E and -K could not be confirmed.
Supporting Information
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